Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Scope Fluidics S.A.. (10/28/20). "Press Release: Prof. Carl Wittwer – the Legendary Creator of the PCR Technology – Joins the Scope Fluidics Advisory Committee". Warsaw.

Organisations Organisation Scope Fluidics S.A.
  Group Scope Fluidics (Group)
  Organisation 2 University of Utah
Products Product PCR|ONE system
  Product 2 PCR technology
  Index term 2 BioFire Diagnostics–Mérieux: investment, 201309–201401 acquisition 100% for $540m in cash by bioMérieux

Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has appointed a new member of the Advisory Committee, Professor Carl Wittwer, a global pioneer in molecular diagnostics, one of the creators of the PCR technology. Prof. Wittwer – currently associated with the University of Utah, Medical School (the USA) – will support the Company in the technological development of its projects. At the same time, Professor Wittwer’s support will bring great global recognition to the Company.

Professor Carl Wittwer is one of the most important authorities in the field of molecular diagnostics technology. In the 1990s, he developed the first PCR (Polymerase Chain Reaction) system, which made it possible to identify genetic material in less than 15 minutes. He is a co-founder of Biofire Diagnostics, which was acquired by Bio Merieux in 2014 for USD 450 million.

Until recently, Professor Wittwer conducted research at the University of Utah, USA. His scientific publications are one of the key inspirations for Scope Fluidics scientists in developing the PCR|ONE system.

Carl Wittwer, Emeritus Professor of Pathology, University of Utah Medical School:

The world needs faster, more accurate diagnostics. The PCR|ONE system from Curiosity Diagnostics is an innovative design for rapid, state-of-the-art RT-PCR identification of SARS-CoV-2 and other targets.  I am pleased to join the Advisory Board of Curiosity Diagnostics and look forward to helping them advance medical diagnostics.

Kamil Gewartowski, PhD, head of the PCR|ONE project in Curiosity Diagnostics, a subsidiary of Scope Fluidics:

When eight years ago we were discussing the concept of building a prototype of an ultra-rapid PCR device, we were inspired by the work of Professor Carl Wittwer, who is an unquestionable guru of the PCR technology and, above all, ultra-fast PCR. His publications motivated us to develop a practical way of implementing ultra-rapid gene detection reactions. We met Professor Wittwer at the AACC conference, where he gave a speech to the audience of thousands of people, while we presented the PCR|ONE system in the Innovation Zone. Professor Wittwer took a keen interest in our system, visited our laboratory in Warsaw, and suggested some very interesting solutions in further discussions. The fact that he is now a member of our team and will support us with his knowledge and experience is a personal distinction and valuable support.

The American professor visited Scope Fluidics at the beginning of last year. He spent a few days getting acquainted with the development of the PCR|ONE system and shared his knowledge and experience at meetings with the Company’s team and a group of representatives of investment funds and consulting agencies.

Scope Fluidics is implementing two projects in the field of molecular diagnostics: the PCR|ONE system and the BacterOMIC system, which address key health care needs. Works on the PCR|ONE system are advanced, and the Company plans to complete the system’s CE-IVD certification and accelerated FDA EUA authorization procedure before the end of this year.

The PCR|ONE system performs fully automatic analysis of bacterial and viral genetic material. The product is unrivalled in terms of speed and complexity of analyses – it can recognize up to several dozen of pathogens within less than twenty minutes of sampling. Recently, the Company has drawn on the strengths of the PCR|ONE system and developed a four-gene test for detecting the SARS-CoV-2 virus. Currently, the PCR|ONE SARS CoV-2 panel is undergoing tests with clinical samples. The panel tests are conducted in a hospital laboratory, on swabs collected directly from patients. The aim of the initiated tests is to verify the effectiveness of the developed panel, which so far has obtained an in-house validation.

The second system, BacterOMIC, solves the problem of effective antibiotic treatment by responding to one of the greatest problems of modern medicine – antimicrobial resistance. Completion of certification and admission of the BacterOMIC system to the medical diagnostics market is planned for mid-2021.

About Scope Fluidics

Scope Fluidics SA is a hub that grows med-tech start-ups, each developing a radical solution to a challenge in global health. The company responds to the global challenges in human health, by designing disruptive diagnostic systems, with the potential to positively impact access to effective healthcare across the world. PCR|ONE system targets healthcare-associated infections and infection control, by offering unprecedented access to molecular Dx information at the point of care. BacterOMIC promises access to precision antibiotic therapies at the price of conventional antibiotic susceptibility testing.

PCR|ONE system is a complete, stand-alone solution for immediate detection of a wide range
of pathogens and genetic targets in the point of care format. The system accepts disposable cartridges that are loaded with clinical samples and automatically processed for detailed diagnosis within 15 minutes. The PCR|ONE system offers a unique combination of record speed and breadth of up to 20 genetic targets that can be identified in a single run, from a single sample.

BacterOMIC is the first system to offer full and actionable information for precision antibiotics therapies. BacterOMIC problems all clinically relevant antibiotics in single test. BacterOMIC is also the first system to offer automated testing of multiple antibiotic combinations.

Record changed: 2020-11-08


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Scope Fluidics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top